Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations.
BACKGROUND
The Brugada syndrome is an arrhythmogenic disease caused in part by mutations in the cardiac sodium channel gene, SCN5A. The electrocardiographic pattern characteristic of the syndrome is dynamic and is often absent in affected individuals. Sodium channel blockers are effective in unmasking carriers of the disease. However, the value of the test remains controversial.


RESULTS
We studied 147 individuals representing 4 large families with SCN5A mutations. Of these, 104 were determined to be at possible risk for Brugada syndrome and underwent both electrocardiographic and genetic evaluation. Twenty-four individuals displayed an ECG diagnostic of Brugada syndrome at baseline. Of the remaining, 71 received intravenous ajmaline. Of the 35 genetic carriers who received ajmaline, 28 had a positive test and 7 a negative ajmaline test. The sensitivity, specificity, and positive and negative predictive values of the drug challenge were 80% (28:35), 94.4% (34:36), 93.3% (28:30), and 82.9% (34:41), respectively. Penetrance of the disease phenotype increased from 32.7% to 78.6% with the use of sodium channel blockers. In the absence of ST-segment elevation under baseline conditions, a prolonged P-R interval, but not incomplete right bundle-branch block or early repolarization patterns, indicates a high probability of an SCN5A mutation carrier.


CONCLUSIONS
In families with Brugada syndrome, the data suggest that ajmaline testing is valuable in the diagnosis of SCN5A carriers. In the absence of ST-segment elevation at baseline, family members with first-degree atrioventricular block should be suspected of carrying the mutation. An ajmaline test is often the key to making the proper diagnosis in these patients.
Hong
Kui
K
Masonic Medical Research Laboratory, 2150 Bleecker St, Utica, NY 13501, USA.
Brugada
Josep
J
Oliva
Antonio
A
Berruezo-Sanchez
Antonio
A
Potenza
Domenico
D
Pollevick
Guido D
GD
Guerchicoff
Alejandra
A
Matsuo
Kiyotaka
K
Burashnikov
Elena
E
Dumaine
Robert
R
Towbin
Jeffrey A
JA
Nesterenko
Vladislav
V
Brugada
Pedro
P
Antzelevitch
Charles
C
Brugada
Ramon
R
D000404:Ajmaline; D004562:Electrocardiography; D005260:Female; D005820:Genetic Testing; D006327:Heart Block / Q000175:diagnosis / Q000235:genetics; D006579:Heterozygote; D006801:Humans; D008297:Male; D062554:NAV1.5 Voltage-Gated Sodium Channel; D010375:Pedigree; D012306:Risk; D012680:Sensitivity and Specificity; D026941:Sodium Channel Blockers; D015222:Sodium Channels / Q000172:deficiency* / Q000235:genetics; D013577:Syndrome; D017180:Tachycardia, Ventricular / Q000175:diagnosis* / Q000235:genetics
D062554:NAV1.5 Voltage-Gated Sodium Channel; C568320:SCN5A protein, human; D026941:Sodium Channel Blockers; D015222:Sodium Channels; D000404:Ajmaline